Private Companies Are BGI Genomics Co., Ltd.'s (SZSE:300676) Biggest Owners and Were Hit After Market Cap Dropped CN¥957m
Private Companies Are BGI Genomics Co., Ltd.'s (SZSE:300676) Biggest Owners and Were Hit After Market Cap Dropped CN¥957m
Key Insights
主要見解
- Significant control over BGI Genomics by private companies implies that the general public has more power to influence management and governance-related decisions
- A total of 3 investors have a majority stake in the company with 52% ownership
- 10% of BGI Genomics is held by Institutions
- 私人公司對華大基因的重要控制意味着大衆對管理和治理決策有更大的影響力。
- 共有3位投資者佔公司的多數股權,擁有52%的所有權。
- 華大基因的10%由機構持有。
If you want to know who really controls BGI Genomics Co., Ltd. (SZSE:300676), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the company with 49% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道誰真正控制着華大基因股份有限公司(SZSE:300676),那麼你就必須看看它的股權登記簿的構成。我們可以看到,私人公司擁有該公司的主要股份,佔有49%。也就是說,如果股票上漲(或經歷下跌),這個集團將獲得最大的利益(或承受最大的損失)。
As a result, private companies as a group endured the highest losses last week after market cap fell by CN¥957m.
結果,私營企業集體承受了上週最大的損失,市值下跌了95700萬人民幣。
Let's delve deeper into each type of owner of BGI Genomics, beginning with the chart below.
讓我們深入了解華大基因的每種所有者類型,從下面的圖表開始。
![1724461908684](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240824/42822215-0-944898ba260b24545126045fb70cdbf4.webp/bigjpg)
What Does The Institutional Ownership Tell Us About BGI Genomics?
機構持股情況說明了華大基因的情況嗎?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。
As you can see, institutional investors have a fair amount of stake in BGI Genomics. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at BGI Genomics' earnings history below. Of course, the future is what really matters.
正如你所看到的,機構投資者在華大基因擁有相當大的股份。這可能表明該公司在投資社區有一定的信譽度。然而,最好謹慎依賴機構投資者的所謂驗證。他們也有時候會犯錯。如果多家機構同時改變對一隻股票的看法,股價可能會快速下跌。因此,查看華大基因的收益歷史也是值得的。當然,未來才是真正重要的。
![1724461910536](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240824/42822215-1-d832ab8e8d19aa5aca11fa036b50da70.webp/bigjpg)
We note that hedge funds don't have a meaningful investment in BGI Genomics. Our data shows that Shenzhen Huada Gene Technology Co., Ltd. is the largest shareholder with 40% of shares outstanding. In comparison, the second and third largest shareholders hold about 9.0% and 2.6% of the stock.
我們注意到,對於華大基因,對沖基金沒有實質性投資。我們的數據顯示,深圳華大基因科技有限公司是最大股東,持有40%的股份。相比之下,第二大和第三大股東持有約9.0%和2.6%的股份。
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
經過更深入的挖掘,我們發現前3大股東共控制了公司股份的一半以上,這意味着他們有相當大的權力來影響公司的決策。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
研究機構所有權是衡量和過濾股票預期表現的好方法。分析師觀點也可以達到相同的目的。我們的信息表明,這隻股票沒有任何分析師覆蓋,所以它可能不是很出名。
Insider Ownership Of BGI Genomics
華大基因的內部持股情況
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
雖然內部人員的精確定義可能具有主觀性,但幾乎所有人都認爲董事會成員是內部人員。管理層最終向董事會負責。然而,如果經理是創始人或CEO,那麼他們成爲執行董事會成員並不罕見。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。
We can report that insiders do own shares in BGI Genomics Co., Ltd.. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around CN¥137m worth of shares (at current prices). Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.
我們可以報告說,BGI Genomics Co., Ltd.的內部人士確實擁有股份。這是一家相當大的公司,因此看到一些可能有意義的利益一致是一個積極的跡象。在這種情況下,他們持有價值約1.37億人民幣的股份(按現價計算)。大多數人會說,這表明了股東和董事會之間的利益一致。不過,還是值得檢查一下這些內部人士是否一直在賣出股份。
General Public Ownership
一般大衆所有權
The general public, who are usually individual investors, hold a 39% stake in BGI Genomics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
普通投資者,通常是個人投資者,持有BGI Genomics 39%的股份。雖然這種所有權的規模可能不足以影響其對政策決策的偏好,但他們仍然可以對公司政策產生集體影響。
Private Company Ownership
私有公司的所有權
We can see that Private Companies own 49%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
我們可以看到,私人企業擁有已發行股份的49%。僅憑這個事實很難得出任何結論,因此值得考慮誰擁有這些私人企業。有時股市公司內部人士或其他相關方通過另外一個私人公司擁有公共公司的股份。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that BGI Genomics is showing 3 warning signs in our investment analysis , and 1 of those makes us a bit uncomfortable...
在考慮公司的不同股東群體時是非常值得的,但還有其他更重要的因素。需要注意的是,我們的投資分析顯示華大基因出現了3個警告信號,其中一個讓我們有些不舒服...
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
當然,這可能不是最好的購買股票。因此,查看這份免費免費的有趣公司列表可能會有所幫助。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。